CJC-1295 (DAC)
CJC-1295 with DAC is a long-acting synthetic GHRH analog studied for sustained GH and IGF-1 stimulation; research protocols typically use about 0.5-2 mg subcutaneously on a roughly weekly schedule.
It has been studied as a long-acting GHRH analog for sustained stimulation of endogenous growth hormone and IGF-1 secretion in research settings.
CJC-1295 with DAC is a synthetic 30-residue analog of growth hormone-releasing hormone (GHRH(1-29)) developed by ConjuChem Biotechnologies. It carries four amino-acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that confer resistance to dipeptidyl peptidase-4 and other plasma proteases, plus a Drug Affinity Complex (DAC) — a maleimidopropionyl-lysine group at position 30 that covalently binds circulating serum albumin. Research has characterized it as a long-acting GHRH-receptor agonist on anterior-pituitary somatotrophs, where it has been studied for stimulating pulsatile growth hormone (GH) synthesis and downstream insulin-like growth factor-1 (IGF-1) secretion.
1 days. CJC-1295 with DAC is not FDA-approved; clinical development was discontinued and it is handled as a research compound only.
Published research used subcutaneous administration on a roughly weekly or biweekly schedule, with single doses around 30-60 micrograms per kilogram identified as the most favorable balance of response and tolerability.
Research reports dose-dependent rises in plasma GH within hours of a single subcutaneous dose, with IGF-1 elevations sustained for roughly 9-11 days and up to 28 days after repeated dosing.
In research and informal protocols it is frequently combined with a growth hormone secretagogue such as ipamorelin or another ghrelin-receptor agonist to recruit a complementary GH-release pathway.
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.